{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AZD6094", "query": { "intervention": "AZD6094" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:27:40.071Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02761057", "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Papillary Renal Cell Carcinoma", "Metastatic Papillary Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Type 1 Papillary Renal Cell Carcinoma", "Type 2 Papillary Renal Cell Carcinoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2016-07-25", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 586, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02761057" }, { "nct_id": "NCT03598244", "title": "Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 41, "start_date": "2018-11-27", "completion_date": "2027-05-27", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03598244" }, { "nct_id": "NCT05261399", "title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma", "Non-Small-Cell Lung" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 341, "start_date": "2022-08-03", "completion_date": "2026-11-23", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 5, "location_summary": "Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05261399" }, { "nct_id": "NCT03258515", "title": "A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "AZD6094 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 45, "start_date": "2017-09-06", "completion_date": "2018-03-24", "has_results": false, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258515" }, { "nct_id": "NCT03778229", "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma" ], "interventions": [ { "name": "osimertinib", "type": "DRUG" }, { "name": "savolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-01-09", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03778229" }, { "nct_id": "NCT02127710", "title": "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Papillary Renal Cell Cancer" ], "interventions": [ { "name": "AZD6094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 111, "start_date": "2014-04-30", "completion_date": "2020-04-20", "has_results": true, "last_update_posted_date": "2021-04-19", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02127710" }, { "nct_id": "NCT03592641", "title": "Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Metastatic Colon Adenocarcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-07-25", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 33, "location_summary": "Los Angeles, California • Sacramento, California • Derby, Connecticut + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03592641" }, { "nct_id": "NCT02143466", "title": "AZD9291 in Combination With Ascending Doses of Novel Therapeutics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Part A - AZD9291 in combination with AZD6094", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with intermittent selumetinib", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with MEDI4736", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with AZD6094", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with selumetinib", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with MEDI4736", "type": "DRUG" }, { "name": "Part C - AZD6094 monotherapy (Japan only)", "type": "DRUG" }, { "name": "Part C - AZD9291 in combination with AZD6094 (Japan only)", "type": "DRUG" }, { "name": "Part D - AZD9291 in combination with AZD6094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 344, "start_date": "2014-08-05", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02143466" }, { "nct_id": "NCT03091192", "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma", "Carcinoma, Renal Cell", "Kidney Neoplasms", "Urologic Neoplasms", "Kidney Diseases", "Neoplasms by Site", "Enzyme Inhibitors", "Protein Kinase Inhibitors" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 60, "start_date": "2017-07-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 8, "location_summary": "La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03091192" }, { "nct_id": "NCT05043090", "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Papillary Renal Cell Carcinoma" ], "interventions": [ { "name": "savolitinib", "type": "DRUG" }, { "name": "durvalumab", "type": "DRUG" }, { "name": "sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 148, "start_date": "2021-10-28", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-02T20:27:40.071Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05043090" } ] }